Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda’s thromboembolism drug enters into Phase II trial
TAK-442 is an oral selective and direct competitive inhibitor of activated Factor X (FXa). As Factor Xa plays a critical role in the blood coagulation cascade, inhibition of
TAK-442 is an oral selective and direct competitive inhibitor of activated Factor X (FXa). As Factor Xa plays a critical role in the blood coagulation cascade, inhibition of
The portable and easy to use single-dose Staccato devices each contain a metal heat package that is chemically heated through a battery- initiated reaction of energetic materials. Alexza
The court, in a modification of its prior opinion, ruled that Warrick’s average wholesale prices (AWPs) had no effect on medicare reimbursement and resulted in no damages to
Under the agreement, Philips’ medical systems division will provide ultrasound devices and technical assistance to ImaRx during laboratory and preclinical studies. The objective of the collaboration is to
Novacea and its partner, Schering-Plough, plan to fully analyze the clinical data to attempt to understand the cause of the higher death rate in the Asentar plus Taxotere
This Phase II study, known as the STRONG Study, evaluated three dose levels of NB S101 (strontium malonate) and one dose level of Protelos, which is approved for
The study was designed to assess the safety and pharmacokinetic properties of ascending dose levels of bavituximab administered as monotherapy in patients with chronic HCV (hepatitis C virus)
This Phase II trial in 10 dialysis and predialysis chronic kidney disease (CKD) patients with pure red cell aplasia (PRCA) evaluated the effectiveness and safety of Hematide administered
The primary objective of the trial was to evaluate the tolerability of ascending doses of the investigational product as determined by the incidence and severity of reported adverse
Under the terms of the transaction, Stiefel will utilize Allergan’s proprietary technology and tazarotene in several ways. Stiefel will co-promote Allergan’s Tazorac (tazarotene) to dermatologists in the US.